Optimizing early detection of uterine cancer in women with risk factors
M. Yu. Grafskaya,
E. V. Verenikina,
A. Yu. Maksimov,
A. A. Demidova,
N. V. Karasenko,
M. V. Ermilova https://doi.org/10.25789/YMJ.2025.89.03
Abstract
The article describes the stages of early detection of uterine body cancer in patients with morbid obesity. It has been proven that genetic testing for oncogenic mutations of endocervical canal scrapings with a negative cytological conclusion regarding cervical cancer is effective for subsequent screening of uterine body cancer. In morbid obesity, the diagnostic sensitivity of mutation screening for uterine body cancer increases when examining endocervical canal scrapings. When oncogenic mutations are detected in samples from the endocervical canal, the next step is recommended to conduct a cytological examination of endometrial biopsies with sampling using brush technology.
About the Authors
M. Yu. Grafskaya
Национальный медицин. исслед. центр онкологии Минздрава России
Russian Federation
Russian Federation
E. V. Verenikina
Национальный медицин. исслед. центр онкологии Минздрава России
Russian Federation
Russian Federation
A. Yu. Maksimov
Национальный медицин. исслед. центр онкологии Минздрава России
Russian Federation
Russian Federation
A. A. Demidova
Ростовский гос. медицин. ун-т Минздрава России
Russian Federation
Russian Federation
N. V. Karasenko
Ростовский гос. медицин. ун-т Минздрава России
Russian Federation
Russian Federation
M. V. Ermilova
Первый Московский гос. медицин. ун-т им. И.М. Сеченова
Russian Federation
Russian Federation
References
1. Adherence to ESGO guidelines and impact on survival in obese patients with endometrial cancer: a multicentric retrospective study / Ouasti S. [et al] // Int J Gynecol Cancer. 2023 Dec 4. No 33(12). 1950-1956. doi: 10.1136/ijgc-2023-004642.
2. Association between weight-adjusted-waist index and gynecologic cancers: a population-based study / Fang L. [et al] // Front Nutr. 2024 Sep 13. No 11. 1449643. doi: 10.3389/fnut.2024.1449643.
3. Evaluation of DNA from the Papanicolaou test to detect ovarian and endometrial cancers / Kinde I. [et al] // Sci. Transl. Med. 2013. No 5. 167ra4.
4. Evaluation of liquid from the Papanicolaou test and other liquid biopsies for the detection of endometrial and ovarian cancers / Wang Y. [et al] // Sci Transl Med. 2018 Mar 21. No 10(433). eaap8793. doi: 10.1126/scitranslmed.aap8793.
5. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries / Bray F. [et al] // CA Cancer J Clin. 2018. No 68(6). 394–424. doi: 10.3322/caac.21492.
6. Identifying molecular mediators of the relationship between body mass index and endometrial cancer risk: a Mendelian randomization analysis / Hazelwood E. [et al] // BMC Med. 2022 Apr 19. No 20(1). 125. doi: 10.1186/s12916-022-02322-3.
7. Onstad M.A., Schmandt R.E., Lu K.H. Addressing the role of obesity in endometrial cancer risk, prevention, and treatment // J Clin Oncol. 2016. No 34(35). 4225–4230. doi: 10.1200/JCO.2016.69.4638
8. Potential value of circulating tumor DNA in gynecological tumors / Liu K. [et al] // Am. J. Transl. Res. 2020. No 12. 3225–3233.
9. The impact of morbid obesity on survival of endometrial cancer / Güzel A.B. [et al] // Turk J Obstet Gynecol. 2020 Sep. No 17(3). 209-214. doi: 10.4274/tjod.galenos.2020.83773.
Review
For citations:
Grafskaya M.Yu., Verenikina E.V., Maksimov A.Yu., Demidova A.A., Karasenko N.V., Ermilova M.V. Optimizing early detection of uterine cancer in women with risk factors. Yakut Medical Journal. 2025;(1):13-16. https://doi.org/10.25789/YMJ.2025.89.03
Views:
68
Email this article 